Evidence map›Paper›PMID 40699435›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Synergistic potential and challenges of immunotherapy combined with radiotherapy in metastatic castration-resistant prostate cancer: a review of mechanisms and clinical advances.

Zengzhao Wei, Xuan Lan, Encun Hou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zengzhao WeiGraduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Xuan LanGraduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Encun HouRuikang Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi, China. houencun1138@163.com.ORCID http://orcid.org/0009-0007-2214-0062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) remains a formidable clinical challenge, with conventional therapies yielding limited efficacy. Immunotherapy combined with radiotherapy (iRT) holds synergistic potential for mCRPC, though mechanistic complexities-including dose-dependent immunomodulation, temporal sequencing dynamics, and tumor microenvironment (TME)-mediated resistance-require further clarification. Radiotherapy enhances tumor immunogenicity by inducing antigen release, improving HLA expression, and activating T cells, thereby potentiating immunotherapy. Clinical trials validate iRT's efficacy: for example,

Indexed as

ImmunotherapyProstatic Neoplasms, Castration-ResistantCombined Modality TherapyHumansMaleTumor MicroenvironmentImmune checkpoint inhibitorsImmunotherapyMetastatic castration-resistant prostate cancerRadiotherapySynergistic effect

Identifiers

PMID40699435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.